These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10022727)

  • 1. The relevance of urethral resistance in children with myelodysplasia: its impact on upper urinary tract deterioration and the outcome of conservative management.
    Tanaka H; Kakizaki H; Kobayashi S; Shibata T; Ameda K; Koyanagi T
    J Urol; 1999 Mar; 161(3):929-32. PubMed ID: 10022727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of children with myelodysplasia: urological alternatives.
    Klose AG; Sackett CK; Mesrobian HG
    J Urol; 1990 Dec; 144(6):1446-9. PubMed ID: 2231940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An analysis of risk factors for upper urinary tract deterioration in patients with myelodysplasia.
    Seki N; Akazawa K; Senoh K; Kubo S; Tsunoda T; Kimoto Y; Naito S
    BJU Int; 1999 Oct; 84(6):679-82. PubMed ID: 10510115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome analysis of vesicoureteral reflux in children with myelodysplasia.
    Agarwal SK; Khoury AE; Abramson RP; Churchill BM; Argiropoulos G; McLorie GA
    J Urol; 1997 Mar; 157(3):980-2. PubMed ID: 9072629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prophylactic value of clean intermittent catheterization and anticholinergic medication in newborns and infants with myelodysplasia at risk of developing urinary tract deterioration.
    Kasabian NG; Bauer SB; Dyro FM; Colodny AH; Mandell J; Retik AB
    Am J Dis Child; 1992 Jul; 146(7):840-3. PubMed ID: 1496955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preservation of renal function in children with myelomeningocele managed with basic newborn evaluation and close followup.
    Hopps CV; Kropp KA
    J Urol; 2003 Jan; 169(1):305-8. PubMed ID: 12478177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clean, intermittent catheterization of infants with neurogenic bladder.
    Joseph DB; Bauer SB; Colodny AH; Mandell J; Retik AB
    Pediatrics; 1989 Jul; 84(1):78-82. PubMed ID: 2740179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vesicoureteral reflux in children with myelodysplasia: natural history and results of treatment.
    Sidi AA; Peng W; Gonzalez R
    J Urol; 1986 Jul; 136(1 Pt 2):329-31. PubMed ID: 3723683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postpubertal urodynamic and upper urinary tract changes in children with conservatively treated myelomeningocele.
    Almodhen F; Capolicchio JP; Jednak R; El Sherbiny M
    J Urol; 2007 Oct; 178(4 Pt 1):1479-82. PubMed ID: 17706702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of reflux in children with myelodysplasia managed by bladder pressure monitoring.
    Flood HD; Ritchey ML; Bloom DA; Huang C; McGuire EJ
    J Urol; 1994 Nov; 152(5 Pt 1):1574-7. PubMed ID: 7933207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of children with myelodysplasia, complicated by vesicoureteral reflux].
    Burkov IV; Nikolaev SN; Prityko AG; Bystrov AV
    Vestn Ross Akad Med Nauk; 1994; (3):51-3. PubMed ID: 7516225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relevance of detrusor hyperreflexia, vesical compliance and urethral pressure to the occurrence of vesicoureteral reflux in myelodysplastic patients.
    Kobayashi S; Shinno Y; Kakizaki H; Matsumura K; Koyanagi T
    J Urol; 1992 Feb; 147(2):413-5. PubMed ID: 1732605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of primary valve ablation versus urinary tract diversion in patients with posterior urethral valves.
    Farhat W; McLorie G; Capolicchio G; Khoury A; Bägli D; Merguerian PA
    Urology; 2000 Oct; 56(4):653-7. PubMed ID: 11018624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Early Oxybutynin Treatment on Posterior Urethral Valve Outcomes in Infants: A Randomized Controlled Trial.
    Abdelhalim A; El-Hefnawy AS; Dawaba ME; Bazeed MA; Hafez AT
    J Urol; 2020 Apr; 203(4):826-831. PubMed ID: 31821098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Vesicoureteral reflux and urinary incontinence in myelodysplastic patients: a comparison between those who had anti-reflux surgery alone and those who were treated by anti-reflux surgery combined with bladder augmentation with or without sling operation].
    Tsuji Y; Saito M; Kondo A; Narushima M; Otani T
    Nihon Hinyokika Gakkai Zasshi; 1998 Jan; 89(1):43-9. PubMed ID: 9493421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endoscopic treatment of vesicoureteral reflux in patients with myelodysplasia.
    Yokoyama O; Ishiura Y; Seto C; Uchibayashi T; Ohkawa M
    J Urol; 1996 Jun; 155(6):1882-6. PubMed ID: 8618279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonsurgical management of threatened upper urinary tracts and incontinence in children with myelomeningocele.
    Hernandez RD; Hurwitz RS; Foote JE; Zimmern PE; Leach GE
    J Urol; 1994 Nov; 152(5 Pt 1):1582-5. PubMed ID: 7933209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urodynamic dysfunction in walking myelodysplastic children.
    Dator DP; Hatchett L; Dyro FM; Shefner JM; Bauer SB
    J Urol; 1992 Aug; 148(2 Pt 1):362-5. PubMed ID: 1635136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for end stage renal disease in children with posterior urethral valves.
    DeFoor W; Clark C; Jackson E; Reddy P; Minevich E; Sheldon C
    J Urol; 2008 Oct; 180(4 Suppl):1705-8; discussion 1708. PubMed ID: 18708224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urethral dilation as treatment for neurogenic bladder.
    Kiddoo DA; Canning DA; Snyder HM; Carr MC
    J Urol; 2006 Oct; 176(4 Pt 2):1831-3; discussion 1834. PubMed ID: 16945663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.